“Should anti-CGRP monoclonal antibodies always be the drug of first choice for migraine prophylaxis in Brazil? – a pharmacoeconomic study”, Headache Med, vol. 15, no. Supplement, p. 98, Aug. 2024, Accessed: Jan. 22, 2026. [Online]. Available: https://headachemedicine.com.br/hm/article/view/1230